Current Opinion in Pulmonary Medicine最新文献_第4页

Current hot topics in pulmonary hypertension. 当前肺动脉高压研究热点。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1097/MCP.0000000000001194

Katarina Zeder, Gabor Kovacs

引用次数: 0

Moving past multidisciplinary discussions and Gender-Age-Physiology model: precision medicine through biological phenotyping in interstitial lung disease. 跨越多学科讨论和性别-年龄-生理模型：通过间质性肺疾病的生物表型进行精准医学。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-09-01 Epub Date: 2025-07-11 DOI: 10.1097/MCP.0000000000001199

Manoj V Maddali, Justin M Oldham, Catharina C Moor

{"title":"Moving past multidisciplinary discussions and Gender-Age-Physiology model: precision medicine through biological phenotyping in interstitial lung disease.","authors":"Manoj V Maddali, Justin M Oldham, Catharina C Moor","doi":"10.1097/MCP.0000000000001199","DOIUrl":"10.1097/MCP.0000000000001199","url":null,"abstract":"Purpose of review: Interstitial lung disease (ILD) presents significant diagnostic and therapeutic challenges due to underlying biological heterogeneity and variable clinical course. Traditional diagnostic and prognostic tools are limited in their ability to capture this heterogeneity or guide personalized treatment. Advances in biological phenotyping have set the stage for precision medicine in ILD, improving diagnosis, prognosis, and therapeutic decision-making in ILD. This review highlights recent advances in biological phenotyping technologies and their potential to reshape ILD care.Recent findings: Emerging evidence supports the use of genomic, transcriptomic, and proteomic, and metabolomic biomarkers to identify distinct ILD subgroups with prognostic or therapeutic relevance. Several biomarkers are being evaluated prospectively, including TOLLIP genotype and eNose technology. Machine learning enables the integration of high-dimensional multiomics data, offering insights beyond what single biomarkers can provide.Summary: Precision medicine in ILD is advancing rapidly and holds promise for more individualized care. Future efforts should prioritize multimodal integration, prospective validation across diverse ILD subtypes, and translating research into clinical practice. Continued innovation and collaboration will be essential to fully realize the potential of precision medicine in transforming ILD care and research.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"504-511"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ANCA associated pulmonary fibrosis: vasculitis or not vasculitis. ANCA相关性肺纤维化：是否为血管炎。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-09-01 Epub Date: 2025-06-23 DOI: 10.1097/MCP.0000000000001187

Helena Codes-Méndez, Diego Castillo, Patricia Moya-Alvarado, Ana Giménez-Palleiro, Ivan Castellvi

{"title":"ANCA associated pulmonary fibrosis: vasculitis or not vasculitis.","authors":"Helena Codes-Méndez, Diego Castillo, Patricia Moya-Alvarado, Ana Giménez-Palleiro, Ivan Castellvi","doi":"10.1097/MCP.0000000000001187","DOIUrl":"10.1097/MCP.0000000000001187","url":null,"abstract":"Purpose of review: The intersection of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) represents a complex and increasingly recognized clinical challenge. This review aims to summarize current understanding, highlight diagnostic and therapeutic approaches, and identify key gaps in the literature regarding ANCA-associated ILD.Recent findings: ANCA positivity-particularly MPO-ANCA- is increasingly identified in patients with fibrotic ILD, even in the absence of systemic vasculitis. This overlap raises questions about disease classification and management, especially as radiologic patterns such as usual interstitial pneumonia (UIP) appear to predict prognosis. Immunosuppressive therapy remains the mainstay of treatment, though its role varies depending on the presence of systemic features and lung fibrosis. Emerging biomarkers, and the potential role of antifibrotic agents offer promising avenues for improved monitoring and therapy.Summary: ANCA-ILD represents a heterogeneous and underexplored disease spectrum that challenges existing classification systems. A multidisciplinary approach is critical, and prospective studies are urgently needed to redefine diagnostic criteria and guide treatment strategies in order to improve clinical outcomes.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"484-493"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering sarcoidosis immunopathogenesis through systems biology. 通过系统生物学解读结节病的免疫发病机制。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-09-01 Epub Date: 2025-07-15 DOI: 10.1097/MCP.0000000000001202

Aiham H Jbeli, Elliott D Crouser, Maneesh Bhargava

{"title":"Deciphering sarcoidosis immunopathogenesis through systems biology.","authors":"Aiham H Jbeli, Elliott D Crouser, Maneesh Bhargava","doi":"10.1097/MCP.0000000000001202","DOIUrl":"10.1097/MCP.0000000000001202","url":null,"abstract":"Purpose of review: Sarcoidosis is a complex, multisystem disease characterized by granulomatous inflammation and variable clinical outcomes. Its pathogenesis and progression are driven by intricate biological interactions, involving a complex interplay between patient-specific factors such as genetic background, sex, and environmental exposures, as well as epigenetic modifications that regulate gene expression and protein levels. These interconnected layers ultimately drive immune response to yet unidentified trigger(s), culminating in granuloma formation and, in some cases, with an aberrant repair response leading to irreversible organ dysfunction in some cases. In this review, we aim to synthesize recent multiomics research that unravels the underlying biological networks, offering a systems-level understanding of sarcoidosis.Recent findings: Recent studies have identified several potential robust biomarkers, including microRNAs, CD14, LBP, HBEGF, eNAMPT, and ANG-2, while also highlighting the central role of the PI3K/AKT pathway in immune activation. Additionally, new noninvasive methods, such as extracellular vesicle profiling, have emerged as promising alternatives to traditional tissue biopsies.Summary: We highlight recent findings from transcriptomics, epigenomics, and proteomics. These studies illuminate key molecular pathways that may be crucial in sarcoidosis pathogenesis, offering promising opportunities to identify novel therapeutic targets that could transform clinical management and improve patient outcomes.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"526-533"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-associated pneumonitis: focus on diagnosis and underlying mechanisms. 免疫检查点抑制剂相关性肺炎：关注诊断和潜在机制

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1097/MCP.0000000000001175

Mtanis Khoury, Saadia A Faiz, Ajay Sheshadri

{"title":"Immune checkpoint inhibitor-associated pneumonitis: focus on diagnosis and underlying mechanisms.","authors":"Mtanis Khoury, Saadia A Faiz, Ajay Sheshadri","doi":"10.1097/MCP.0000000000001175","DOIUrl":"10.1097/MCP.0000000000001175","url":null,"abstract":"Purpose of review: This review aims to provide an updated overview of the diagnosis, risk factors, and treatment strategies for immune checkpoint inhibitor (ICI) pneumonitis, with a particular emphasis on its underlying pathophysiology.Recent findings: Recent advances, such as single-cell RNA sequencing of bronchoalveolar lavage fluid and the identification of biomarkers, including autoantibodies, are enhancing our understanding of ICI-related pneumonitis. These findings suggest that both cell-mediated and humoral mechanisms contribute to the pathophysiology of the condition.Summary: Pneumonitis can significantly limit the efficacy of life-saving cancer treatments, such as ICIs. Although corticosteroids are the first-line treatment according to guidelines, steroid-refractory pneumonitis remains common and is associated with high mortality. Emerging data is providing a more detailed understanding of the dysregulated immune response responsible for pneumonitis, which may guide the development of targeted therapies and direct future research efforts.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"335-343"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of pharmacotherapy in lung transplant candidates. 肺移植候选者的药物治疗管理。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1097/MCP.0000000000001172

Katelyn N Rudzik, Haifa Lyster

{"title":"Management of pharmacotherapy in lung transplant candidates.","authors":"Katelyn N Rudzik, Haifa Lyster","doi":"10.1097/MCP.0000000000001172","DOIUrl":"10.1097/MCP.0000000000001172","url":null,"abstract":"Purpose of review: Lung transplantation is a common treatment for end-stage lung disease (ESLD). Patients present to lung transplantation evaluation on various medications that could impact their candidacy and posttransplant course. In this review, we will discuss pretransplant optimization of pharmacotherapy to minimize complications while waiting for transplant and increase posttransplant success. We will also discuss important considerations for posttransplant immunosuppression, antimicrobial prophylaxis, and complex drug interactions.Recent findings: Prior to lung transplantation, several medications should be optimized to promote posttransplant success including minimization of corticosteroids, opioids, and benzodiazepines. Lung transplantation candidates should be up to date on vaccinations. Most medications for ESLD are well tolerated to continue up until the point of transplant including antifibrotics, CFTR modulators, and pulmonary vasodilators. Mammalian target of rapamycin inhibitors and other immunosuppressants may need to be stopped or minimized before lung transplantation to minimize posttransplant infection and would healing complications. Medications that increase risk of posttransplant bleeding, thrombosis, or aspiration should be stopped prior to listing.Summary: In this article, we discuss management of pharmacotherapy for lung transplantation candidates to minimize posttransplant complications. Changes in medications for ESLD should be done cautiously to prevent worsening of native disease while waiting for lung transplantation.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"387-396"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infections and lung transplantation: key considerations for eligibility, management, and posttransplant care. 感染和肺移植：资格、管理和移植后护理的关键考虑因素。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MCP.0000000000001177

Jonathan Huang, Rachel Friedman-Moraco, Stephanie Pouch

{"title":"Infections and lung transplantation: key considerations for eligibility, management, and posttransplant care.","authors":"Jonathan Huang, Rachel Friedman-Moraco, Stephanie Pouch","doi":"10.1097/MCP.0000000000001177","DOIUrl":"10.1097/MCP.0000000000001177","url":null,"abstract":"Purpose of review: Lung transplantation is a critical and evolving therapy for patients with end-stage lung disease. As the need for lung transplantation increases, careful candidate selection is vital to maximizing outcomes and ensuring appropriate organ allocation. A key challenge in lung transplant candidates is the colonization or infection of the lungs by environmental and upper airway pathogens. These lung pathogens, along with other chronic infections, can lead to posttransplant complications with high mortality and an increased risk of graft failure.Recent findings: Major infectious considerations for lung transplantation include colonization or infection by multidrug-resistant bacteria (including Burkholderia cepacia complex), nontuberculous mycobacteria, molds, and chronic viral infections. By recognizing the epidemiology, diagnosis, and management of these infections in the peri-transplant period, transplant providers can better mitigate infectious risks and improve transplant success. Similarly, advancements in diagnostics and therapeutics offer novel approaches to managing previously challenging infections.Summary: As experience grows in treating these difficult infectious syndromes, more candidates are becoming eligible for transplantation. A thorough understanding of infectious considerations in lung transplant candidates is essential for improving candidate selection, reducing posttransplant complications, and expanding transplant eligibility.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"374-380"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy in the management of lung neoplasms: is it ready for prime time? 立体定向体放射治疗在肺肿瘤治疗中的应用：它准备好了吗？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1097/MCP.0000000000001171

Nicholas Eustace, Arya Amini, Jyoti Malhotra, Kristin A Higgins, Terence M Williams, Percy Lee

{"title":"Stereotactic body radiation therapy in the management of lung neoplasms: is it ready for prime time?","authors":"Nicholas Eustace, Arya Amini, Jyoti Malhotra, Kristin A Higgins, Terence M Williams, Percy Lee","doi":"10.1097/MCP.0000000000001171","DOIUrl":"10.1097/MCP.0000000000001171","url":null,"abstract":"Purpose of review: Advances in radiation delivery have expanded the scope of stereotactic body radiation therapy (SBRT) in lung cancer treatment, as it offers better local control, shorter treatments, and enhanced immunostimulation. This review summarizes recent literature regarding SBRT's role in nonoperable and operable early-stage, locally advanced, central, and oligometastatic nonsmall cell lung cancer (NSCLC), and its mixed results with immunotherapy.Recent findings: Recent studies demonstrate SBRT achieves excellent local control in inoperable early-stage NSCLC and is being explored as an alternative to surgery for operable cases. Additionally, SBRT can be done safely in central tumors if strict dose limits to normal structures are observed. SBRT shows promise in locally advanced disease, as consolidative local therapy for oligoprogressive and oligometastatic disease and in combination with immune checkpoint inhibitors. Advances in adaptive radiation therapy and novel fractionation schedules, including ultra-hypofractionation and personalized approaches, further refine SBRT's role in lung cancer management, with more practice changing clinical trials on the horizon.Summary: SBRT provides durable and well tolerated treatment for patients with localized and metastatic lung cancer. With ongoing trials exploring its synergy with immunotherapy and its applicability in operable patients and large tumors, SBRT is poised to play an even greater role in personalized lung cancer treatment.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"326-334"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-05-29 DOI: 10.1097/MCP.0000000000001181

引用次数: 0

Editorial: Integrating the general pulmonologist in the continuum of lung transplantation: a primer on current issues in referral, selection, and posttransplant care. 社论：将普通肺科医生整合到肺移植的连续体中：关于转诊、选择和移植后护理的当前问题的入门。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2025-07-01 Epub Date: 2025-05-29 DOI: 10.1097/MCP.0000000000001182

Carli J Lehr, Caroline Patterson

引用次数: 0